Keyphrases
2-cycles
25%
4-cycle
25%
Advanced Hodgkin's Lymphoma
75%
Bleomycin
25%
Breast
25%
Chemotherapy
100%
Chemotherapy Alone
75%
Combined Modality Therapy
100%
Complete Remission
25%
Dacarbazine
25%
Doxorubicin
25%
Favorable Risk
25%
Few-cycle
25%
First-line Therapy
25%
Heart-lung
25%
Hodgkin Lymphoma
100%
Interim PET
25%
Involved Field Radiotherapy
25%
Late Effects
25%
Limited-stage
100%
Modern Radiotherapy
25%
Palliative Radiotherapy
25%
Patient Selection
25%
Radiotherapy
100%
Risk Profile
25%
Standard of Care
25%
Survival Rate
25%
Treatment Options
25%
Vinblastine
25%
Medicine and Dentistry
Adriamycin Bleomycin Vinblastine Dacarbazine
57%
Bleomycin
14%
Chemotherapy
100%
Dacarbazine
14%
Doxorubicin
14%
Hodgkin's Lymphoma
100%
Involved-Field Radiotherapy
14%
Late Effect
14%
Lung
14%
Multimodality Cancer Therapy
57%
Polyethylene Terephthalate
28%
Radiation Therapy
100%
Survival Rate
14%
Vinblastine
14%
Immunology and Microbiology